March 20, 2023

Volume XIII, Number 79

Advertisement
Advertisement

March 20, 2023

Subscribe to Latest Legal News and Analysis
Advertisement

AG Garland Signals That Department of Justice's Cannabis Policy Will Be "Very Close" To Cole Memorandum

In his March 1, 2023 testimony before the United States Senate, Attorney General Merrick Garland indicated that the Department of Justice's (DOJ) marijuana policy will harken back to 2013, when then-Attorney General James Cole issued what became known as the "Cole Memo." The Cole Memo carved out eight enforcement priorities that DOJ identified as "particularly important," including prevention of distribution of marijuana to minors, revenue from flowing to criminal enterprises, the use of marijuana activity as a front for other illegal acts, and violence or threats to public safety. Otherwise, Attorney General Cole wrote, the federal government intended to rely on state and local law enforcement to address cannabis under their own regulatory schemes.

This hands-off approach guided the federal government's marijuana enforcement efforts until Attorney General Jeff Sessions rescinded the Cole Memo in 2018. Not much changed following rescission, but the cannabis industry welcomed President Biden's announcement in October 2022 indicating prior federal offenses for simple possession of marijuana should be pardoned and requesting that the Department of Health and Human Services and the Attorney General initiate an administrative process to revisit marijuana's classification under the Controlled Substances Act as a Schedule I drug.

AG Garland's testimony brings us full circle back to 2013, and may indicate that the AG does not intend to recommend de-scheduling marijuana.

©1994-2023 Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. All Rights Reserved.National Law Review, Volume XIII, Number 75
Advertisement
Advertisement
Advertisement

About this Author

Jane Haviland, Mintz Levin Law Firm, Complex Commercial Litigation Product Liability & Complex Tort Securities Litigation Health Care Enforcement & Investigations
Associate

Jane’s practice focuses on litigation matters, including health care enforcement defense, complex civil and business litigation, and product liability law. Recent victories to which Jane has contributed include:

  • Defense verdicts on summary judgment in multi-jurisdictional product liability disputes involving FDA-approved pharmaceutical drugs and assay test development.
  • Defense verdict on partial summary judgment in a bet-the-company case involving a dispute between the majority owner of a multi-billion dollar company and private equity investors.

Jane...

617.348.4473
Advertisement
Advertisement
Advertisement